There’s no escaping the rise of AI adoption and integration. It’s not so much a question of whether you will adopt AI into your business practices, but how.
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh